Payment overview · 2025
General Payments
$393.02
26 reported records · 8 companies
Healthcare provider profile · identity verified
John Scott Litton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PENNINGTON GAP, VA · NPI 1417920984
Verified facts
What the public records show
CMS Open Payments records show John Scott Litton, M.D. received $393.02 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.82 | 35.1% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.12 | 15.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.17 | 13.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.92 | 11.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.42 | 8.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.20 | 8.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.41 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.96 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $393.02 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $121.09 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.94 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.12 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.17 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.42 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 151 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
87 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
40 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
151 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 697 | 161 |
| Omeprazole | Omeprazole | 576 | 159 |
| Losartan Potassium | Losartan Potassium | 505 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 127 |
| Gabapentin | Gabapentin | 448 | 80 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 447 | 123 |
| Pregabalin | Pregabalin | 423 | 79 |
| Montelukast Sodium | Montelukast Sodium | 420 | 114 |
| Metformin Hcl | Metformin Hcl | 414 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 58 |
| Meloxicam | Meloxicam | 364 | 114 |
| Fluticasone Propionate | Fluticasone Propionate | 351 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 344 | 94 |
| Lisinopril | Lisinopril | 343 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 340 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 314 | 86 |
| Simvastatin | Simvastatin | 303 | 86 |
| Famotidine | Famotidine | 301 | 83 |
| Tramadol Hcl | Tramadol Hcl | 291 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 84 |
| Buspirone Hcl | Buspirone Hcl | 258 | 67 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 246 | 32 |
| Eliquis | Apixaban | 235 | 44 |
| Potassium Chloride | Potassium Chloride | 226 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 59 |
| Furosemide | Furosemide | 205 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 195 | 52 |
| Fenofibrate | Fenofibrate | 193 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 57 |
| Mirtazapine | Mirtazapine | 181 | 54 |
| Alendronate Sodium | Alendronate Sodium | 178 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 42 |
| Carvedilol | Carvedilol | 160 | 39 |
| Glipizide | Glipizide | 157 | 41 |
| Mounjaro | Tirzepatide | 151 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 148 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 147 | 35 |
| Allopurinol | Allopurinol | 144 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 143 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 141 | 53 |
| Sucralfate | Sucralfate | 138 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 38 |
| Trazodone Hcl | Trazodone Hcl | 134 | 31 |
| Finasteride | Finasteride | 123 | 33 |
| Cefdinir | Cefdinir | 121 | 85 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 30 |
| Naproxen | Naproxen | 117 | 37 |
| Prednisone | Prednisone | 117 | 93 |
| Warfarin Sodium | Warfarin Sodium | 114 | 19 |
| Clonazepam | Clonazepam | 103 | 16 |
| Propranolol Hcl | Propranolol Hcl | 102 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 30 |
| Nabumetone | Nabumetone | 97 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 27 |
| Methocarbamol | Methocarbamol | 96 | 28 |
| Ibuprofen | Ibuprofen | 95 | 35 |
| Donepezil Hcl | Donepezil Hcl | 88 | 21 |
| Chlorthalidone | Chlorthalidone | 87 | 23 |
| Mometasone Furoate | Mometasone Furoate | 87 | 52 |
| Symbicort | Budesonide/Formoterol Fumarate | 87 | 28 |
| Mupirocin | Mupirocin | 86 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 23 |
| Synthroid | Levothyroxine Sodium | 78 | 20 |
| Sertraline Hcl | Sertraline Hcl | 77 | 14 |
| Lorazepam | Lorazepam | 74 | suppressed |
| Nystatin | Nystatin | 73 | 34 |
| Celecoxib | Celecoxib | 70 | 20 |
| Cephalexin | Cephalexin | 69 | 37 |
| Nitroglycerin | Nitroglycerin | 67 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 56 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 15 |
| Topiramate | Topiramate | 55 | suppressed |
| Trulicity | Dulaglutide | 55 | suppressed |
| Atenolol | Atenolol | 53 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 11 |
| Bupropion Hcl | Bupropion Hcl | 51 | 14 |
| Ozempic | Semaglutide | 51 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 41 |
| Meclizine Hcl | Meclizine Hcl | 50 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 50 | suppressed |
| Spironolactone | Spironolactone | 49 | 19 |
| Lansoprazole | Lansoprazole | 47 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 46 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 40 | 30 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 39 | 39 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 36 | 13 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 20 |
| Enalapril Maleate | Enalapril Maleate | 33 | 11 |
| Ezetimibe | Ezetimibe | 33 | 11 |
| Amoxicillin | Amoxicillin | 32 | 31 |
| Ondansetron Odt | Ondansetron | 32 | 14 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 21 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Probenecid | Probenecid | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 17 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Temazepam | Temazepam | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $393.02 · 26 records | ABBVIE INC. | BREZTRI, CAPLYTA, FREESTYLE LIBRE 3, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error